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A cardinal feature of early stages of human brain development centers on the
sensory, cognitive, and emotional experiences that shape neuronal-circuit formation and
refinement. Consequently, alterations in these processes account for many psychiatric
and neurodevelopmental disorders. Neurodevelopment disorders affect 3–4% of the
world population. The impact of these disorders presents a major challenge to
clinicians, geneticists, and neuroscientists. Mutations that cause neurodevelopmental
disorders are commonly found in genes encoding proteins that regulate synaptic
function. Investigation of the underlying mechanisms using gain or loss of function
approaches has revealed alterations in dendritic spine structure, function, and plasticity,
consequently modulating the neuronal circuit formation and thereby raising the
possibility of neurodevelopmental disorders resulting from synaptopathies. One such
gene, SYNGAP1 (Synaptic Ras-GTPase-activating protein) has been shown to cause
Intellectual Disability (ID) with comorbid Autism Spectrum Disorder (ASD) and epilepsy in
children. SYNGAP1 is a negative regulator of Ras, Rap and of AMPA receptor trafficking
to the postsynaptic membrane, thereby regulating not only synaptic plasticity, but also
neuronal homeostasis. Recent studies on the neurophysiology of SYNGAP1, using
Syngap1 mouse models, have provided deeper insights into how downstream signaling
proteins and synaptic plasticity are regulated by SYNGAP1. This knowledge has led to
a better understanding of the function of SYNGAP1 and suggests a potential target
during critical period of development when the brain is more susceptible to therapeutic
intervention.
Keywords: SYNGAP, synaptic plasticity, intellectual disability, autism spectrum disorders, learning and memory,
neurodevelopmental disorders
INTRODUCTION
The brain is the center of the nervous system and is the most complex organ in the body. All
day-to-day activities including executive decisions, memories, emotions, and cognitive tasks
are mediated by the cerebral activity. Apart from coordinating the ability to smell, touch, hear,
taste, and see, the brain enables people to form words, perform mathematical calculations,
communicate using different languages, grasp and appreciate music, make decisions, organize
and plan everyday activities and above all, imagine. Therefore, normal development of brain is
imperative for performing these and other essential functions. A cardinal feature of early stages
of human brain development centers on the sensory, cognitive, and emotional experiences that
shape neuronal-circuit formation and refinement. Consequently, alteration in any of these features
accounts for many psychiatric and neurological disorders (Spooren et al., 2012; Kroon et al., 2013).
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The human brain consists of 86 billion neurons and 85
billion non-neuronal cells (Azevedo et al., 2009), which play
a vital role in information processing and transmission in
the form of electrical signals through specialized junctions
called synapses. Neuroscientists have made great progress in
unraveling the cellular and molecular mechanisms of dendritic
spine synapse formation and function, which is considered as
one of the most remarkable developments in biology in the
last three decades. A precise control of synaptic development
and neuronal connectivity has been found to be necessary
for normal brain development. Conversely, abnormal dendritic
spine morphology and function can lead to disruption of
neuronal circuits, and consequently can result in various
psychiatric and neurodevelopmental disorders (NDDs; Melom
and Littleton, 2011).
Altered dendritic spine function and neuronal circuit
formation account for one of the major underlying mechanisms
of Intellectual Disability (ID) and Autism Spectrum Disorder
(ASD; Chechlacz and Gleeson, 2003; Kroon et al., 2013), which
are often co-diagnosed in young children with NDDs and affect
1–3% of the general population. Due to high rates of co-
morbidity of these NDDs, it has been broadly hypothesized that
ID and ASD share common neurodevelopmental pathologies
that lead to various behavioral and cognitive symptoms that
define these disorders. The underlying cause of these NDDs are
believed to be mutations in genes, parental drug use and aging
process, viral infections and other environmental factors (van
Spronsen and Hoogenraad, 2010).
Recent evidences from many animal models of ID and
ASD suggest that mutations that cause NDDs occur in genes
encoding the proteins that regulate synaptic function and/or
structure (Boda et al., 2002; Bear et al., 2004; Ramocki and
Zoghbi, 2008; Südhof, 2008; Gauthier et al., 2011; Penzes et al.,
2011). Mutations in many of these single-genes are the major
cause of syndromic and non-syndromic ID (NSID; Bhakar
et al., 2012; Zoghbi and Bear, 2012). The most common single-
gene mutations in ASD with ID are associated with Fragile
X syndrome (FXS; FMRI), Tuberous Sclerosis (TSC1, TSC2),
Angelman Syndrome (UBE3A), Rett Syndrome (MECP2), and
Phlean-McDermid syndrome (SHANK3). Rare mutations in
single-genes, such as those encoding for Neuroligin (NLGN3,
NLGN2) and Neurexin (NRXN1), are also implicated in ID
and ASD. These genes are just a few of many implicated
in NDDs, suggesting that highly penetrant mutations of
genes play an important role in regulating synaptic function.
Heterozygous mutation in SYNGAP1 cause ID and ASD, and
whose product is now established as a major regulator of synaptic
function.
Numerous studies have shown that a major share of dendritic
spine synapses utilize the excitatory neurotransmitter, glutamate,
to activate N-methyl D-aspartate receptors (NMDARs), which
are associated with a vast array of transmembrane proteins,
scaffolding proteins and many signaling proteins (Pèrez-Otaño
and Ehlers, 2004; Lau and Zukin, 2007; Kerchner and Nicoll,
2008; Lai and Ip, 2013; Fan et al., 2014). SYNGAP1, is
a downstream component of NMDAR-associated signaling
complex that negatively regulates activation of small GTP-ase
(Ras- and Rap-GAP) and of α-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid receptor (AMPAR) trafficking to
excitatory postsynaptic membrane (Rumbaugh et al., 2006;
Huang, 2009; Walkup et al., 2015). SYNGAP1 is a ∼140 kDa
protein located on Chromosome 6p21.31 (Figure 1; Husi et al.,
2000). Phosphorylation of SYNGAP1 is regulated by CaMKII,
which reduces SYNGAP1’s control of Ras-GTPase, leading to
Ras activation by increasing the GTP-bound form of Ras. It is
now established as a major signaling protein that plays a pivotal
role in regulating fundamental molecular changes in dendritic
spine synaptic morphological and functional modifications.
Moreover, mutations in SYNGAP1 are established as relevant
for human pathology, because they have been associated
with ID comorbid with ASD in children (Hamdan et al.,
2009, 2011a,b, 2014; Gauthier et al., 2011; Berryer et al.,
2013).
Until a few years ago, the neurophysiological mechanism
that causes ID in patients with SYNGAP1 mutation was not
clear. Using mouse models of Syngap1 heterozygous mutations
(Syngap1−/+), several labs have shown that 50% reduction
of the level of SYNGAP1 is sufficient to cause significant
increases in the presence of mushroom-shaped dendritic spines
during early stages of development resulting from a lack
of inhibition of Ras-GTPase, which in turn allows more
AMPARs to be transported to the postsynaptic membrane.
Moreover, it has been shown that in Syngap1−/+ models
certain critical periods of neuronal growth and maturation
are disrupted, leading to developmental brain disorders, that
in turn cause cognitive and social dysfunctions (Guo et al.,
2009).
Syngap1 EXPRESSION, FUNCTIONAL
DOMAINS, AND ISOFORMS
SYNGAP1 is a ∼140 kDa protein, first characterized by Chen
et al. (1998) using a mouse model of Syngap1−/+ mutation
and followed by Kim et al. (1998) who developed a truncated
form of SYNGAP1 using yeast two-hybrid system (See Table 1
for Historical perspective). Based on these studies, it can be
understood that the N-terminal half of SYNGAP1 has a Ras-
GAP domain, along with the region that is loosely homologous
to Pleckstrin homology and a C2 domain which is potentially
involved in binding of Ca2+and phospholipids. Interestingly,
the alignment of GAP domain of SYNGAP1 with other Ras-
GAPs suggests that the amino acids in GAP domain are vital
for interaction with Ras and for the stimulation of Ras-GTPase
activity (Chen et al., 1998; Kim et al., 1998). Given the Ras-
GAP-interacting domain of a newly discovered protein and
its presence in excitatory synapses (Chen et al., 1998; Kim
et al., 1998), this protein was termed SYNGAP1 (Synaptic Ras-
GAP activator protein). Moreover, studies have shown that
SYNGAP1 is expressed only in brain tissue and not in other
tissues (Chen et al., 1998; Kim et al., 1998). In the brain, it
is primarily expressed in the excitatory neurons, where it is
localized to synapses. On the contrary, SYNGAP1 was absent
1http://www.ncbi.nlm.nih.gov/gene/8831
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FIGURE 1 | Amino acid sequence of human SYNGAP1 and its difference with mouse SYNGAP1. Amino acid sequence differences of SYNGAP1 between
Homo sapiens (SYGP1_Human), Rattus rattus (SYGP1_RAT) and Mus musculus (SYGP1_MOUSE). Variations in the sequences were indicated in red colored fonts.
Dashed line indicates empty sequences.
in inhibitory neurons. Chen et al. (1998) have shown that the
carboxyl terminal tail of SYNGAP1 interacts with postsynaptic
density protein (PSD-95), as confirmed by their coprecipitation
(Kim et al., 1998). In addition, Kim et al. (1998) have shown
that the C-terminal half consists of a repeat of 10 histidines
that may be involved in metal chelation, several potential
serine and tyrosine phosphorylation sites and a T/SXV motif
necessary for interaction with SAP102 and PSD-95. This study
further suggested that SYNGAP1 is a cytosolic protein without
a signal peptide or any transmembrane domain (Kim et al.,
1998).
Studies have shown that functionally distinct proteins may be
produced via regulated alternate splicing of mRNA (Lipscombe,
2005; Li et al., 2007; Grabowski, 2011; Raj and Blencowe,
2015). It is evident that Syngap1 is a complex gene that
gives rise to multiple protein domains. This further implies
that Syngap1 may be spliced differentially, which can lead to
different isoforms. Indeed, Chen et al. (1998) showed that two
splice variants were observed, one at the amino terminus and
one at carboxyl terminus, which further encode four variants
with molecular weights of 134, 137, 140 and 143 KDa. The
amino acid terminal contains a putative Pleckstrin homology
(PH) domain (Chen et al., 1998), which may attach the
protein to the membrane (Lemmon and Ferguson, 2000). In
support of this finding, a recent study has identified distinct
isoforms of SYNGAP1 (Figure 2), differing in their N- and C-
terminals (McMahon et al., 2012). The existence of different
isoforms was further confirmed when anti-SYNGAP1 antibody
recognized doublet or triplet of proteins at 130 kDa only in
the brain, with no detection of SYNGAP1 and its isoforms
in any other parts of the body such as kidney, heart or lung
(Chen et al., 1998; Kim et al., 2003). Each isoform contains
a central GAP domain to regulate the activity of GTPase in
small GTPases such as Ras and Rap. Three distinct Syngap1
isoforms, SYNGAP A, B and C, differing in their N-termini
arising from different promoter regions have been identified
(McMahon et al., 2012). A and B isoforms contain unique peptide
sequence and a complete PH domain, whereas isoform C is a
shorter, truncated protein with no unique peptide sequence and
no PH domain. Furthermore, SYNGAP A, B, and C isoforms
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TABLE 1 | Historical perspective of major findings of SYNGAP1.
Observation/findings of SYNGAP1 Referrences Model/samples
First Syngap1 Het mouse model Chen et al. (1998) Mouse
Binds to CaMKII /PSD95 Chen et al. (1998) Mouse
Kim et al. (1998) Yeast two-hybrid hippocampal cDNA library
Amino acid sequences and molecular weight Chen et al. (1998) Mouse
Kim et al. (1998) Yeast two-hybrid hippocampal cDNA library
Husi et al. (2000) Mouse
McMahon et al. (2012) Mouse
Domain structure of SYNGAP1 and Isoforms Chen et al. (1998) Mouse
McMahon et al. (2012) Mouse
Localized in excitatory neurons Chen et al. (1998) Mouse
Kim et al. (1998)
Kim et al. (1998) Yeast two-hybrid hippocampal cDNA library
Syngap1 Homozygous mice die within a week Komiyama et al. (2002) Mouse/Primary neuronal culture
Kim et al. (2003) Mouse/cortical culture
Synaptic transmission and LTP Komiyama et al. (2002) Mouse/Primary neuronal culture
Kim et al. (2003) Mouse/cortical culture
Learning and Memory deficits Komiyama et al. (2002) Mouse/Primary neuronal culture
Altered ERK, Ras, Rac p-Cofilin Komiyama et al. (2002) Mouse/Primary neuronal culture (ERK)
Carlisle et al. (2008) Mouse/Hippocampi neuronal culture
Dendritic spine structure Vazquez et al. (2004) Mouse/primary neuronal culture
Carlisle et al. (2008) Mouse/Hippocampi neuronal culture
Cognitive and social dysfunction Guo et al. (2009) Mouse
Muhia et al. (2010) Mouse
Intellectual disability in children Hamdan et al. (2009) Human
Prematuration of dendritic spines Clement et al. (2012) Mouse
Aceti et al. (2015) Mouse (in vivo)
Altered critical period of plasticity Clement et al. (2013) Mouse
This table summarizes the major findings/observations of function of SYNGAP1 by various groups.
can be subdivided based on transcription start sites (A1–A11;
B1; C1–C8). To determine whether the multiple promoters were
also present in humans, a sequence comparison with mouse
and rat revealed a highly conserved regions with no predicted
functional moieties (McMahon et al., 2012). Finally, alternate
splicing of Syngap1 mRNA leads to multiple isoforms of C-
termini, designated as α, β and γ. Of these, the most studied
C-terminus isoform is SYGNAP1 α1, which contains the PDZ-
binding domain and mediates binding to scaffolding proteins
of PSD.
The expression of various genes that encode proteins
regulating synaptic formation and function are shown to reach
their peak level of expression during early stages of development.
Moreover, several of these proteins have recently been implicated
in ID (State and Levitt, 2011; State and Sestan, 2012). Indeed,
expression of SYNGAP1 in neurons reaches its peak 14 days after
birth, i.e., at Postnatal day 14 (PND 14 days) in rodents (Kim
et al., 1998; Clement et al., 2012), but steadily decreases to adult
level by 2 months of age (Porter et al., 2005). Further, SYNGAP1
is highly expressed in hippocampus and cortex, and less in
striatum (Komiyama et al., 2002). The expression of SYNGAP1
was reduced by 50% in Syngap1−/+ mice (Komiyama et al., 2002;
Kim et al., 2003; Clement et al., 2012). However, no abnormal
gross development of brain was observed in Syngap1−/+ mice
(Kim et al., 2003).
It is well known that development and synaptic activity plays
a major role in differential splicing of genes involved in synaptic
function. The N-termini SYNGAP1 isoforms, A and B had a
pattern of regulation during development (gradual increase in
expression till PND14), while isoform C was expressed at very
low level till PND14 (McMahon et al., 2012). However, all
three isoforms, A, B, and C reached their peak expression at
PND14. Further, it is shown that Syngap B and C were up-
regulated two-fold after 4 h of bicuculline treatment, whereas
SYNGAP A was down-regulated (McMahon et al., 2012). These
changes were inhibited in the presence of tetrodotoxin. This
confirms that differential splicing of Syngap1 occurs based on
neuronal activity, which leads to opposing functional effects
of Syngap1 isoforms; SYNGAP A had silencing effect, while
SYNGAP B and C had positive effect on synaptic transmission
and strength. Unlike N-termini isoforms, the protein levels
of C-termini isoforms did not change when stimulated with
bicuculline. Importantly, it is not clear from previous studies
which combination of N- and C- termini isoforms exists in
neurons. Using isoform-specific antibodies, it is clear that
both C-terminal isoforms exist in hippocampus and cortex
(McMahon et al., 2012; Yang et al., 2013) and that α2-containing
isoforms localize to PSDs, although they do not contain a QTRV
region to bind to PDZ domain. This could be because, when
non-phosphorylated CaMKII is inactive at rest, both isoforms
are localized within PSD core and α1 binding to PSD-95 serves
a distinct function, that of blocking the other portions from
binding to PSD-95. Furthermore, upon activation of NMDARs,
both α1 and α2 isoforms move out of the PSD core, but this
change was reversed within 30–45 min following the NMDAR
activation.
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FIGURE 2 | SYNGAP1 isoforms arising from alternate splicing. (A) A schematic illustration of potential SYNGAP1 isoforms, which vary in both N- and
C-termini. (B) Amino acid sequences that are unique to different N- and C-termini isoforms identified by mass spectrometry (McMahon et al., 2012).
This movement of SYNGAP1 α1 and α2 out of PSD
core could have two significant effects. The first major
effect could be a displacement of GAP activity and thus
induces activity-dependent synaptic modification (Yang et al.,
2013; Araki et al., 2015). The second major effect of
SYNGAP1 α1 and α2 isoforms moving out of the PSD
core is to create an empty slot for the association of an
AMPAR (Yang et al., 2013), thereby regulating synaptic
strength. In fact, overexpression of SYNGAP1 α1 isoform
reduces AMPAR-mediated miniature excitatory postsynaptic
currents (mEPSCs), whereas overexpression of SYNGAP1
α2 isoform enhances mEPSCs. Nevertheless, these studies
illustrate the fact that different isoforms exert opposing
effects on synaptic strength and that both full peptide
sequences, N- and C-terminal, and their isoforms must be
considered when examining the functional properties of the
protein.
SYNGAP1 MUTATIONS IN INTELLECTUAL
DISABILITY
ID, formerly characterized as Mental Retardation, is defined
by three criteria: (a) an intelligent quotation of less than 70;
(b) limitations in two or more adaptive behaviors such as
communication, self-care and social skills, community use, self-
direction, health, and safety; and (c) evidence that the mental
manifestations began before the age of 18 (van Bokhoven,
2011). ID comprises a diverse collection of syndromic and
non-syndromic disorders. Unlike NSID, which is characterized
by intellectual deficits as the only clinical feature, syndromic
ID patients typically exhibit other abnormal clinical features,
such as cranial, facial, and skeletal dysmorphisms. Major causes
of ID and ASD stem from mutations of genes encoding for
proteins that are critical regulators of synaptic function. De novo
mutations in individual genes explain an important aspect of
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NSID characterized by the absence of associated morphologic,
radiologic and metabolic features, as opposed to ID associated
with more complex chromosomal aberrations (Ropers and
Hamel, 2005). The genetic factors involved in NSID are not
clearly known. So far, 29 X-linked and five autosomal recessive
genes have been identified by linkage and cytogenetic analysis
(Bienvenu and Chelly, 2006; Chelly et al., 2006; Gécz et al.,
2009). In addition, mutations in autosomal dominant genes are
still to be identified in NDDs, as ID and ASD result in lower
reproductive probability, which further reduces the chances of
identifying families that are open to linkage analysis. Yet, de
novo mutations are the most commonly recognized cause of ID,
which suggests that monoallelic lesions are sufficient to cause
this disorder. In fact, studies have shown that one to three de
novo mutations per zygote affect amino acid sequences (Crow,
2000a,b, 2006).
In the past decade, novel autosomal de novo mutations were
identified in genes encoding for proteins involved in synaptic
plasticity. In relation to that, recent studies from children have
shown that de novo truncating mutations in SYNGAP1 cause
NSID (Hamdan et al., 2009, 2011a,b, 2014; Berryer et al., 2013).
Hamdan et al. (2009) identified protein-truncating de novo
mutations in SYNGAP1 in 3 of 94 patients with NSID. These
patients ranged from 4–11 years and had similar clinical features
as described in the Mullen Scale of Early Learning and the
Vineland Adaptive Behavior Scales (Hamdan et al., 2009). Of
those three patients, two patients were heterozygous for nonsense
mutations, while the third patient was heterozygous for a frame-
shift mutation starting at codon 813, producing a premature
stop codon at 835. All these children were born to non-
consanguineous parents. During early stages of development,
these children presented with hypotonia and global delay of
development with the onset of walking at 2-years. Apart from
these defects, two of these children had presented with tonic-
clonic and myoclonic seizures.
In order to further explore the association of SYNGAP1 to
ID, particularly to understand whether patients with epilepsy
and ASD had SYNGAP1 de novo mutations, Hamdan et al.
(2011a) sequenced exons of SYNGAP1 from additional cohorts
of patients.De novo out-of-frame deletions were identified in two
patients with NSID presented with microcephaly and generalized
epilepsy. The authors also described a de novo splicing mutation
in a patient with autism that had not acquired microcephaly
or epilepsy (Refer to Table 2). Moreover, missense mutations
in SYNGAP1 were detected in three patients. Surprisingly,
all these patients were born to non-consanguineous parents.
Furthermore, other studies (Krepischi et al., 2010; Zollino
et al., 2011; Writzl and Knegt, 2013) have identified de novo
microdeletions in chromosome region 6p21.3 in patients with ID,
epilepsy and severe language impairment. Therefore, it is evident
from the studies that heterozygous mutations in SYNGAP1 are
the major cause of NSID.
SYNGAP1 IN SCHIZOPHRENIA
Although several studies have shown the role of Syngap1
mutations in neurodevelopmental disorders, a little is known
about its relevance to schizophrenia. Converging evidence
suggest that dysfunction of NMDARs and the signaling
complex associated with them is now considered to be
one of the major causes of schizophrenia (Belsham, 2001).
Hypofunction of NMDARs was first implicated when reduced
concentration of glutamate were found in the cerebrospinal
fluid of patients with schizophrenia (Kim et al., 1980).
The alteration in the function of activation-ready NMDAR
complexes localized in the PSD can lead to a defect in
downstream signaling pathways. It has been shown that a
major function of SYNGAP1 is to transduce the activation
of synaptic NMDA receptors to a biochemical signal that is
necessary for proper neuronal function. Therefore, SYNGAP1
and its interacting proteins may be abnormal in patients with
schizophrenia.
A study by Funk et al. (2009) has shown that SYNGAP1
and its interacting proteins, such as PSD95, were reduced in
patients with schizophrenia. Interestingly, patients who were
non-medicated for 6 weeks prior to the time of their death
showed decreased levels of SYNGAP1 compared to medicated
patients. A similar observation was made for SYNGAP1-
interacting proteins such as PSD-95. This study hypothesized
that SYNGAP1−/+ are associated with schizophrenia-like
behavioral phenotypes. Indeed, reduced expression of SYNGAP1
results in abnormal behaviors that are strikingly similar
to that reported in mice with reduced NMDAR function
(Guo et al., 2009). This suggests that proteins downstream
of NMDAR, including SYNGAP1, participate in a common
pathway that may be dysfunctional in people with schizophrenia.
However, other studies (Hamdan et al., 2009) did not find
any de novo mutations, splicing or truncating, in their
patients with schizophrenia. As the sample number of patients
with schizophrenia studied in their work is low, more
samples are needed to confirm the role of SYNGAP1 Het in
schizophrenia.
MOUSE MODELS OF Syngap1
The recent advances in genomic science and the development
of transgenic technology in mice have advanced research
into the effect of monoallelic mutations in genes that
are associated with synaptic transmission and neuronal
circuit formation. SYNGAP1 is highly conserved across
species (McMahon et al., 2012), which has allowed for the
development of different animal models of Syngap1−/+ mice
(Komiyama et al., 2002; Kim et al., 2003; Vazquez et al.,
2004; Muhia et al., 2010). The SYNGAP1 mouse ortholog,
Syngap1, is located on chromosome 172. Interestingly,
Syngap1−/− mutant mice do not survive for more than a
week (Kim et al., 2003). This is due to increased levels of
caspase-3 activation in Syngap1−/−, which suggests that
apoptosis is enhanced by reduction of SYGNAP1 (Knuesel
et al., 2005). The different animal models of Syngap1−/+
are extensively discussed in a recent review (Ogden et al.,
2015).
2http://www.ncbi.nlm.nih.gov/gene/240057
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TABLE 2 | Clinical features observed in patients with SYNGAP1 heterozygous mutation.
Patient no Gene DNM Age Sex ID Epilepsy Cranial MRI/CT
1 SYNGAP1 p.Lys138X 4 yrs. 5 months F ++/+++ GN Normal/ND
2 SYNGAP1 p.Arg579X 5 yrs. 10 months F ++/+++ GN Normal/ND
3 SYNGAP1 p.Leu813ArgfsX23 12 yrs. 10 months F ++/+++ – ND/Normal
4 STXBP1 p.Arg388X 15 yrs. F +++ PC Normal/Normal
5 STXBP1 c.169–1G>A 27 yrs. F +++ PC ND/Normal
6 SHANK3 c.601–1G>A 15 yrs. M + – ND/Normal
7 KIF1A p.Thr99Met 3 yrs. 5 months F +++ – Atrophy/ND
8 GRIN1 p.Glu662Lys 10 yrs. F ++ – ND/Normal
9 GRIN1 p.Ser560dup 7 yrs. 6 months M +++ PC Normal/ND
10 EPB41L1 p.Pro854Ser 6 yrs. M +++ – Normal/ND
11 CACNG2 p.Val143Leu 8 yrs. M ++ – Normal/ND
12 KIFC1, PHF1, CUTA, SYNGAP1 – 6 yrs. M ++ – Normal/ND
13 SYNGAP1, CUTA, PHF1 – 5 yrs. F +++ GN Normal/ND
14 SYNGAP1, CUTA, PHF1 – 9 yrs. M ++ PC Normal/ND
Summary of clinical features observed in patients with SYNGAP1 heterozygous mutation. ID Scale: + denotes mild, ++ moderate, +++ severe. Abbreviations used ND,
not determined; PC, Partial complex epilepsy; GN, Generalized epilepsy. These features are based on different sources (Hamdan et al., 2009, 2011a,b, 2014; Krepischi
et al., 2010; Zollino et al., 2011; Berryer et al., 2013; Writzl and Knegt, 2013).
Due to a rapid increase in the availability of the types of
genetically modified mice (Branchi et al., 2003), it is critical
to meticulously characterize their biochemical, pathological and
behavioral features and compare them with human phenotypes
(Bailey et al., 2006; Crawley, 2008). Generally, laboratories
involved in testing the phenotypes of genetically modified
mice subject them to a battery of behavioral features to
assess cognitive, motor, and sensory functions. In addition, to
consider a genetically modified mouse as a disease model, the
transgenic animal must fulfil at least two levels of validity to
judge its psychopharmacology (van der Staay et al., 2009). An
animal model should score high on the following validities:
face validity, i.e., resemblances of behavioral phenotypes of
mouse model to that of human disorder; construct validity,
i.e., closely reconstructs and mimics the underlying cause
of the disease or disorder; and predictive validity, i.e., drug
treatments alleviate symptoms in mouse and human. A mouse
model should fulfil at least face and construct validity. Indeed,
various mouse models of Syngap1−/+ mice satisfied face validity
(Komiyama et al., 2002; Kim et al., 2003; Guo et al., 2009;
Muhia et al., 2010). These various Syngap1−/+ mouse models
recapitulated many of the phenotypes observed in humans.
For example, Komiyama et al. (2002) were the first to observe
learning and memory deficits in Syngap1−/+ mice. Using a
different model described by Kim et al. (2003), Syngap1−/+
mice displayed altered social/conspecific interaction, abnormal
spatial working memory, decreased anxiety-related response,
hyperactivity, impaired cued conditioning behavior, increased
startle reflex, increased horizontal stereotypic behavior and
reduced prepulse inhibition, as well as learning deficits (Guo
et al., 2009). Later, using another genetic model of Syngap1−/+
mice (Muhia et al., 2010), Muhia et al. observed cognitive
dysfunctions similar to the Guo et al. (2009) study. As
mentioned previously, epilepsy is a prominent clinical feature
observed in SYNGAP1 patients. Accordingly, Syngap1−/+ mice
are prone to audiogenic seizures and have reduced seizure
threshold and altered electroencephalogram (EEG; Clement
et al., 2012; Ozkan et al., 2014). Therefore, based on these
studies, it is clear that mouse models of Syngap1−/+ (Ogden
et al., 2015) mutation phenocopy the deficits observed in
SYNGAP1 patients, thereby allowing a better understanding
of SYNGAP1−/+ mutation in neuronal function and its
consequence in ID.
ROLE OF Syngap1 IN NEUROLOGICAL
PATHWAY
For nearly two decades, neuroscientists have studied SYNGAP1-
related signaling pathways. Synapses are extremely ordered
structures that facilitate the transmission of information from
presynaptic terminal to the postsynaptic membrane and,
subsequently, activate signal transduction cascades that lead to
suitable cellular events. In the postsynapticmembrane, twomajor
ionotropic glutamate receptor subtypes are present—NMDARs
and AMPARs. NMDARs are glutamate-sensitive ion channels
that open up when glutamate and its co-agonist are bound
to them. However, the actual permeation of ions through
NMDAR channels occurs after the removal of Mg2+ block
achieved by depolarization of the postsynaptic membrane. This
depolarization is induced by glutamate binding to AMPARs.
Subsequently to activation of NMDARs in the postsynaptic
membrane, Ca2+ enters the dendritic spine, triggering activation
of kinase cascades and thereby mediating various synaptic
functions (Fan et al., 2014). NMDARs are an integral component
of the PSD and bind to several PSD-enriched scaffold and
signaling molecules, resulting in creation of a vast protein
complex (Niethammer et al., 1996; Kennedy, 1997; Xu, 2011).
This NMDAR-PSD protein complex is believed to play a vital role
in the precise tuning of synapses in response to changing input
stimuli pattern (Grant and O’dell, 2001; Yashiro and Philpot,
2008). SYNGAP1, one of the most abundant proteins in the
PSD, is associated with NMDAR protein complex (Figure 3),
which was first shown by Chen et al. (1998) and followed
by Kim et al. (1998). Establishing SYNGAP1’s role in the
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NMDAR-mediated protein complex and signaling cascade is
important to further our understanding of the etiology of
SYNGAP1-mediated ID and ASD (Figure 3). SYNGAP1 has
been shown to co-immunoprecipitate with PSD-95 protein
complex from deoxycholate-solubilized mouse brain membrane
preparations (Chen et al., 1998; Kim et al., 1998).
The GAP domain of SYNGAP1 is homologous to that
of p120GAP and neurofibromin, two canonical Ras-GAPs
that do not regulate Rap (Chen et al., 1998; Kim et al.,
1998). However, SYNGAP1 has been shown to regulate Rap-
GTPase more potently than Ras-GTPase (Pena et al., 2008).
A recent study by Walkup et al. (2015) has shown that
recombinant SYNGAP1 lacking 102 residues at the N-terminus
is phosphorylated by cyclin-dependent kinase 5 (CDK5), as
well as by CaMKII. Interestingly, phosphorylation of SYNGAP1
by CDK5 and CaMKII increases overall SYNGAP1 activity,
but also alters the ratio of its GAP activity towards Ras-
and Rap-GTPases. Phosphorylation of SYNGAP1 by CaMKII
increases its Ras-GAP activity by 25% and its Rap-GAP
activity by 76%. CDK5 increases recombinant SYNGAP1
activity on Ras-GAP by 98% and its Rap-GAP activity
by 20%. Furthermore, upon NMDAR stimulation, Ca2+
entering the synapse dissociates CaMKII from SYNGAP1 and
phosphorylates SYNGAP1 (pSYNGAP1). This leads to activation
of Ras that activates proteins downstream, consequently to
AMPAR insertion in the postsynaptic membrane. Therefore,
the phosphorylation of SYNGAP1 is believed to be important
in regulating transient changes in the number of surface
AMPA receptors or gradually adjusting their steady-state
level.
By biochemical analysis of proteins containing the GAP,
Krapivinsky et al. (2004) have identified the C2 domain as
essential for the Rap-GAP activity of SYNGAP1, which is in line
with the recent observation (Walkup et al., 2015). The homology
of SYNGAP1 with other Ras-GAP domains across species and in
vivo associations of SYNGAP1with theNMDA receptor complex
indicate that SYNGAP1 plays a role in Ras-mediated signaling
in excitatory synapses, particularly in response to Ca2+ (Kim
et al., 1998; Carlisle et al., 2008). Apart from regulating Ras-
mediated signaling, SYNGAP1 has been shown to mediate the
activity of other major signaling proteins, such as Rac, p-Cofilin,
p21-activated kinase (PAK) and LIMK (Carlisle et al., 2008) and
these proteins were shown to be elevated at basal conditions in
Syngap1−/+ mice.
ROLE OF SYNGAP1 IN REGULATING
DENDRITIC SPINE MORPHOLOGY AND
PLASTICITY
The neuronal signaling cascades underlying synaptic plasticity
and dendritic spine structure have been intensely studied and a
multitude of signaling molecules have been identified (Kennedy
et al., 2005; Patterson and Yasuda, 2011). Initial stages of
dendritic spine formation and neuronal connections depend
on cytoskeleton protein, F-actin, which is regulated by Ras-
and Rac-GTPases. Therefore, it is possible that the dendritic
spine structure and function would be altered in Syngap1−/+
mutations, which may explain the behavioral deficits observed
in SYNGAP1−/+ patients.
Ras- and Rac-mediated signaling cascade, including
ERK and MAPK, has also been shown to play a major
role in normal synaptic transmission and in long-term
potentiation (LTP; Carlisle and Kennedy, 2005; Kennedy
et al., 2005) by modulating insertion of AMPARs into
the postsynaptic membrane (Figure 3). On the contrary,
opposite effects were observed in Syngap1 knockout in
neuronal cultures using small interfering RNA. Studies from
neuronal culture have demonstrated that overexpression
of Syngap1 resulted in a remarkable down regulation of
AMPAR-mediated currents (Rumbaugh et al., 2006). In
contrast, AMPAR-mediated currents were increased in
Syngap1−/+ in neuronal cultures treated with small interfering
RNA.
Under basal conditions, when fEPSPs, which are
predominantly mediated by AMPARs, were measured from
adult mouse CA1 hippocampal pyramidal region, Syngap1−/+
mice did not show any abnormal excitatory synaptic responses
(Komiyama et al., 2002). Furthermore, the presynaptic fibers
were required to evoke an equivalent postsynaptic response in
slices from wild type (WT), and Syngap1−/+ mouse responses
were not altered suggesting that the activity of postsynaptic
AMPARs were unchanged. However, these experiments were
performed in adults and the genes encoding the proteins that
regulate synaptic function reach their peak level of expression
during early stages of development (State and Levitt, 2011;
State and Sestan, 2012). Indeed, Syngap1 Het mutations can
affect synaptic transmission during early developmental period.
Thus, Vazquez et al. (2004) have reported that the Syngap1−/+
mice form dendritic spines and synapses prematurely, and that
spines ultimately become larger in Syngap1−/+. In addition,
Clement et al. (2012, 2013) have shown elevated input-output
relationship in extracellular field recording and AMPAR-
mediated mEPSCs, which reached WT adult level 2 weeks
after birth (PND14), confirming the earlier findings (Vazquez
et al., 2004). These studies suggest that SYNGAP1 controls
the trajectory of synapse maturation during a particular
period of development by controlling protein synthesis and
homeostatic synaptic plasticity during development (Wang et al.,
2013).
In hippocampal pyramidal neurons, spine structure is
tightly correlated with synaptic function (Noguchi et al.,
2011). Syngap1−/+ mutation disrupts proper development of
dendritic spine structures. Syngap1−/+ mice have more mature,
mushroom-shaped spines during early stages of development
(PND14) suggesting precarious prematuration of dendritic
excitatory spine structures (Clement et al., 2012, 2013). Further,
accelerated spine formation and premature spine pruning have
been observed in developing neocortical tissue of Syngap1−/+
mice (Aceti et al., 2015). These abnormalities observed during
development in Syngap1−/+ mutation persisted into adulthood
(Vazquez et al., 2004; Carlisle et al., 2008; Clement et al.,
2012), consistent with the spine dysfunction theory of cognitive
disorders.
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FIGURE 3 | Signaling mechanism upon phosphorylation of SYNGAP1. Schematic model of the cellular events that link CaMKII activity to phosphorylation of
SYNGAP1 and its regulation of downstream molecules. Glutamate receptors, such as NMDAR and AMPAR, are clustered at the postsynaptic active zone with a
dense matrix called PSD. Upon NMDAR activation, Ca2+ enters the postsynaptic cytosol, triggering phosphorylation of CaMKII, which in turn phosphorylates
SYNGAP1 (pSYNGAP1). pSYNGAP1 regulates Ras-GTPases controlling actin dynamics and AMPARs insertion into the postsynaptic membrane. In Syngap1
Heterozygous mutation, the inhibition of Ras activation by SYNGAP1 (shown as #) is lost, which increases Ras activity, thereby increasing AMPAR exocytosis to the
postsynaptic membrane. Phosphorylation of SYNGAP1 by cyclin-dependent kinase 5 (CDK5) activates Rap1 that increases endocytosis of AMPAR. It is not clear
how pSYNGAP1 regulates other SYNGAP1-associated proteins such as Cdc42, Rac1 (dotted orange lines), which are yet to be studied.
Altered maturation of dendritic spine morphology and
function can lead to various learning and memory deficits
(Peca et al., 2011; Goncalves et al., 2013). Indeed, patients with
SYNGAP1 Het mutations were observed to have learning and
memory deficits (Hamdan et al., 2009, 2011a). To understand the
impact of early maturation of dendritic spine morphology and
function on learning and memory in Syngap1−/+ mice, synaptic
plasticity studies were carried out by various labs. There are two
major forms of synaptic plasticity, LTP and LTD (long term
depression), which have been considered to represent the cellular
correlates of learning and memory and are both dependent on
local protein synthesis (Volianskis et al., 2015). Deficits in LTP
have been observed in many animal models of ID and ASD
(Volk et al., 2007, 2015; Pavlowsky et al., 2012). Alterations
in signaling proteins function can lead to anomalous synaptic
plasticity and dendritic spine structure and can correlate with
Frontiers in Cellular Neuroscience | www.frontiersin.org 9 February 2016 | Volume 10 | Article 32
Jeyabalan and Clement SYNGAP1: Mind the GAP
cognitive impairments in patients with ID and ASD (McKinney,
2005; Penzes et al., 2011; van Bokhoven, 2011; Kroon et al.,
2013). Interestingly, adult Syngap1−/+ mice do show reduced
LTP in the CA1 hippocampal region, which is likely due to
reduced activation of Ras and ERK during LTP (Komiyama
et al., 2002; Kim et al., 2003; Ozkan et al., 2014), suggesting
that reduced level of SYNGAP1 derepresses the resting levels of
activated Ras and ERK. Additionally, SYNGAP1 has been shown
to rapidly disperse from spines during and after LTP because of
the phosphorylation of SYNGAP at Ser1108/1138 by CaMKII.
Subsequently, SYNGAP1 activates Ras, which triggers long-term
changes in spine size, suggesting the inhibition of stable LTP by
SYNGAP1 (Araki et al., 2015).
CRITICAL PERIOD OF PLASTICITY
Steady increase of synaptic AMPARs and subsequent functional
unsilencing of glutamatergic inputs are characteristics of early
postnatal development (Kerchner and Nicoll, 2008). Premature
acquisition of functional AMPARs during development is
suggestive of an acceleration of neurodevelopmental pattern
during a critical period of development. A critical period is a
regulated time window during which the sensory experience
and intrinsic neuronal activity provide information that are
essential for normal development and refinement of neuronal
circuits (Meredith et al., 2012). Any alteration to dendritic spine
structure and function during this critical period can have a
lasting effect on cognitive functions, the development of which
requires the formation and refinement of synaptic networks of
neurons in the brain. Precariously high AMPAR/NMDAR ratios
observed in Syngap1−/+mice could lead to altered duration of
plasticity-related critical periods. In the thalamocortical pathway,
generation of LTP becomes difficult towards the end of the
first postnatal week (Crair and Malenka, 1995). However, high
frequency stimulation failed to elicit LTP in PND4 and PND7
in Syngap1−/+ mice, while LTP was generated in PND4 WT
animals. Given that SYNGAP1 has been shown to suppress
AMPAR insertion in the postsynaptic membrane, the main
explanation for LTP failure at synapses would be a precocious
unsilencing of the developing thalamocortical pathway. Indeed,
Syngap1−/+ mice have altered unsilencing of post-synapses
during early stages of development in the thalamocortical
pathway (Clement et al., 2013) and altered formation and
elimination of dendritic spines (Aceti et al., 2015). These studies
further confirm the hypothesis that prematuration of dendritic
spine structure due to accumulation of AMPAR at synapses
shortens the duration of the critical window of plasticity leading
to altered behavioral function (Figure 4).
In addition to LTP, another form of synaptic plasticity,
LTD is important for proper formation and refinement of
neuronal connections (Feldman and Knudsen, 1998; Hensch,
2005). Thus, it would be predicted that thalamocortical synapses
exhibits LTP as well as LTD. Similar to LTP, the amount
of LTD induced in thalamocortical connections exhibited a
developmental reduction with little or no depression remaining
by P10–12 (Feldman et al., 1998). This signals the end of
critical period of plasticity in thalamocortical synapses. In
addition, this study suggests that NMDAR dependent LTD
modulates the efficacy of synapses previously unsilenced by
LTP (Daw et al., 2007), thereby, allowing the synapses to
modulate the connections based on the input specific activity.
However, it is not clear LTD can induce resilencing of functional
synapses during critical period of development. Given the
importance of LTD in critical period of plasticity, it is not clear
whether LTD is altered during critical period of development in
Syngap1−/+mice.
PROPOSED MODEL OF Syngap1−/+
MUTATION IN NEURONAL DEVELOPMENT
AND MATURATION
One of the common features observed in most forms of ID is
the inability to develop and maintain normal dendritic spine
architecture and proper function at synapses, which lead to
abnormal neuronal connections. Based on the above discussion,
it is evident that Syngap1−/+ mutations lead to abnormal
dendritic spinematuration during development. All mutations in
Syngap1 are predicted to truncate the protein, thus decreasing the
ability of SYNGAP1 to bind to the molecules downstream in the
signaling pathway. Phosphorylation of SYNGAP1 is regulated
by CaMKII, which reduces SYNGAP1’s control of Ras-GTPase,
leading to Ras activation by increasing the GTP-bound form
of Ras. Further, phosphorylation of SYNGAP1 by CaMKII
increases the ratio of Rap1-GAP to Ras-GAP (Walkup et al.,
2015). This would shift the steady-state balance of AMPAR
trafficking at the synapse towards exocytosis by decreasing the
level of active Rap1 compared to active Ras, which would result
in an increased surface AMPAR. In contrast, phosphorylation of
SYNGAP1 by CDK5 decreases its ratio of Rap1-GAP to Ras-GAP
activity, which would allow more AMPAR to be endocytosed
from the postsynaptic surface. Therefore, SYNGAP1 negatively
regulates Ras activation and insertion of AMPA receptors in the
postsynaptic membrane. Phosphorylation of SYNGAP1 creates
transient changes in the number of AMPARs and gradually
adjusts the steady-state level of AMPARs in the postsynaptic
membrane (Figure 3). However, due to Syngap1−/+ mutation,
truncated SYGNAP1 fails to inhibit Ras activity, thereby
facilitating conversion of inactive, GDP-bound Ras to an active,
GTP-bound form and increasing the level of Ras activation. Ras
is one of the important components of the signaling pathway
underlying NMDA receptor mediated activation of ERK (Iida
et al., 2001). Thus, increase in Ras activity elevates the level of
phosphorylated ERK, which further facilitates the insertion of
AMPARs to the postsynaptic membrane (Derkach et al., 2007).
In this aspect, SYNGAP1 is a key molecule that facilitates a cross
talk between CaMKII and Ras/MAPK signaling pathways that
leads to AMPAR trafficking, thereby controlling the excitatory
synaptic strength, particularly in developing neurons. However,
SYNGAP1’s control of excitatory synaptic strength during
development is lacking in ID patients or in the Syngap1−/+ mice
model.
Furthermore, increased level of Ras activation leads to
activation of LIMKII, CDC42 and p-cofilin, which regulate actin
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FIGURE 4 | Schematic model of the impact of Syngap1 haploinsufficiency on neuronal circuit function. This figure illustrates the impact of Syngap1
heterozygous mutation on dendritic spine morphology, neuronal connection organization, and behavioral phenotypes. Heterozygous mutations in Syngap1 lead to
prematuration of dendritic spine morphology during early stages of development (A). This causes abnormal formation and elimination of spines that leads to altered
spine density and excitatory neuronal connections during development in the cortex (Aceti et al., 2015). Further, the abnormal cortical excitatory neuronal
connections lead to E/I imbalance during early stages of development, which persists, into adult stages in Syngap1 Hets (B). Consequently, these abnormalities
bring about altered duration of critical period of development (C), which leads to cognitive and social dysfunction (D). PND, Post-natal Day. The gene products
implicated in intellectual disability (ID) and/or autism spectrum disorder (ASD) are marked in Red color text. Some features are modified with permission based on
Clement et al. (2012).
cytoskeleton (Figure 3). Actin is the major cytoskeletal element
in dendritic spines, where it serves both as framework for
the spine structure and as a scaffold for postsynaptic proteins
(Dillon and Goda, 2005). Cofilin is best known as a regulator
of actin whose assembly and disassembly depends upon the
concentration of cofilin. In Syngap1−/+ mice, increased levels
of p-Cofilin shift the equilibrium towards the more stable actin
form, F-actin. This makes the dendritic spine more stable at
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an early stage of development. Thus, more stable form of
actin combined with an increase in insertion of AMPAR into
the postsynaptic membrane during development (PND14–16 in
hippocampus in Hets) causes the dendritic spines to mature into
mushroom shaped spines, which occurs earlier in Syngap1−/+
than in WT animals (Figure 4).
This leads to elevated excitatory synaptic transmission
causing Excitatory/Inhibitory (E/I) imbalance, particularly
during the critical period of development. Due to the altered
E/I balance, humans, as well as Syngap1−/+ mice, are prone
to epileptic seizures. The altered E/I balance observed in
Syngap1−/+ mice is representative of an altered form of synaptic
homeostasis that degrades the ability of mature neurons to
optimally balance excitation relative to inhibition. Indeed,
truncation of SYNGAP1 occludes the ability of neurons to scale
up synaptic strength in response to activity, suggesting that
SYNGAP1 associated signaling is necessary for maintaining
homeostatic synaptic plasticity (Wang et al., 2013). In fact,
altered dendritic spine morphology and function during the
critical period of development causes a coordinated acceleration
of dendritic elongation, spine formation, and elimination
(pruning) in cortical neurons, which may result in altered
neuronal connectivity and abnormal closure of critical period
plasticity (Figure 4). Interestingly, E/I imbalance in Syngap1−/+
mutation leads to altered pruning of spines, which in turn causes
abnormal connections (non-target) in neurons and negatively
affects the organization of neuronal circuits (Aceti et al., 2015).
The abnormal pruning of spines and connections between
neurons could be a consequence of an altered duration of critical
period observed in Syngap1−/+ mice. This would prevent the
neuronal connections to be actively refined by the surrounding
environment in which the individual exists.
There appear to be independent critical periods of
development for different modalities, ranging from basic
visual processing to language and social skills, which are
observed to be affected in patients with SYNGAP1 heterozygous
mutation. Syngap1−/+ mice displayed early closure of critical
period of plasticity during development (Clement et al., 2013).
The precise development of the timing of critical periods during
cortical development is essential for the proper organization
of synaptic connections and neuronal circuit formation. Thus,
premature closure of plasticity window during development
could contribute to altered refinement of cortical circuits that
persist throughout the life of an animal and thus contributing
to cognitive deficits in Syngap1−/+ mice. Thus, transient
neurodevelopmental events induced by Syngap1 mutations
could cause life-long disruptions to cognition and behavior that
are difficult to treat in adulthood.
ROLE OF ASTROCYTES IN ID AND ASD
While neurons are considered as major players in brain function
such as perception, social behavior and memory, astrocytes
have been relegated to a far lesser supporting role. However,
in recent years, emerging evidences suggest that signaling
between astrocytes and neurons at the tripartite synapse plays
an important role during the critical period of development
(Stevens, 2008; Clarke and Barres, 2013). Although astrocytes
were considered to play a passive onlooker in the synapse, but
studies show that, they are necessary for neuronal maturation,
function, and development of neurons. During early stages
of development, astrocytes and neurons are formed from
neuronal precursor cells (Freeman, 2010). Three-dimensonal
reconstructions of dye-filled astrocytes reveal that astrocytes
extend thousands of intricate processes that are organized
into large, non-overlapping anatomical domains. It has been
estimated that a single astrocyte can associate with multiple
neurons and over 100,000 synapses (Bushong et al., 2002; Halassa
et al., 2007a,b). While astrocytes are incapable of generating
action potentials, they do secrete a wide array of gliotransmitters
and express many of the same channels, receptors and cell surface
molecules similar to neurons (Haydon, 2000; Fields and Stevens-
Graham, 2002; Fiacco and Mccarthy, 2006).
Neurons rely on astrocytes to instruct the formation and
elimination of their synapses lead to the possibility that astrocytes
work in parallel with and interacts with, the neuronal processes
that control circuit formation. One of the first evidences that
astrocytes contribute majorly in critical period of development
came from a study by Muller and Best (1989) that injection
of immature astrocytes into the adult visual cortex reopened
the window of ocular dominance plasticity. Further, a study
from purified rodent ganglion cells (RGCs) suggested that RGCs
formed very few syanpses in the absesnce of astrocytes. However,
when cultured in the presence of astrocytes, or in a medium
that had been conditioned with any other soluble signals released
by astrocytes, RGCs can form ten-fold more excitatory synapses
and synaptic functionality was increased (Pfrieger and Barres,
1997; Ullian et al., 2001). Not only astrocytes regulate the
development, maturation, and function of excitatory neurons,
they are a requisite for the development of inhibitory synapses.
Liu et al. (1996) showed that local contact between neurons
and astrocytes significantly increased the amplitude and density
of GABAA receptors in developing hippocampal neurons. In
addition, astrocytes were shown to regulate chloride ion gradient
in cultured spinal cord neurons and convert GABAergic neurons
from excitatory to inhibitory (Li et al., 1998). These studies
suggest that immature astrocytes are necessary for critical period
of development and it is linked to maturation of astrocytes.
It is evident from the above mentioned studies that astrocytes
play a major role in normal neuronal development and
function, it would not be surprising that astrocytes contribute
in some capacity to almost all pathological conditions of the
nervous system (Lin and Koleske, 2010; Parpura et al., 2012).
Consequently, astrocyte-dysregulated function has been linked
with the progressive pathology of ischemic stroke, epilepsy and to
a number of neurodegenerative disorders including amyotrophic
lateral sclerosis, Huntington’s disease, Parkinson’s disease, Rett
syndrome, FXS, and autism (Yamamuro et al., 2015). FXS is one
of the most common form of ID and affects 1 in 4000 males and
1 in 6000 females. Fragile X mental retardation protein (FMRP)
is reported to be expressed in Oligodendritic precursor cells but
not mature oligodendrocytes (Wang et al., 2004). However, a
study by Pacey and Doering (2007) reported expression of FMRP
in astrocytes. Further, they showed that WT neurons grown
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on Fmr1 KO astrocytes exhibited significantly altered dendritic
arbor morphologies, whereas Fmr1 KO neurons cultured with
WT astrocytes, the alterations in dendritic morphologies and
synaptic protein expression were prevented (Jacobs and Doering,
2010; Jacobs et al., 2010). These experiments were the first to
suggest that astrocytes contribute to the normal development
of dendritic spine morphology and function. Therefore, it
is important to study the role of astrocytes in Syngap1−/+
mutations. However, there are no studies to date to suggest
expression of Syngap1 in astrocytes or its role in ID due to
Syngap1−/+.
CONCLUSION
Basic research in ID and ASD using model organisms has
been critical in advancing our understanding of many NDDs.
Important insights into the neurophysiology of Syngap1−/+
mutations, especially the regulation of dendritic spine formation
and function, has been gained from the study of Syngap1−/+
mouse models. Although it is clear from these studies that
SYNGAP1 is a negative regulator of AMPAR insertion in the
postsynaptic membrane that regulates dendritic spine structure
and function, certain questions still remain unanswered, such
as which downstream proteins are regulated by affected by
Syngap1−/+ mutations. The other major question is to find the
precise window during development to address the symptoms
observed in ID. In fact, repairing pathogenic Syngap1−/+
mutation after the end of critical period of development failed
to rescue neurophysiological and cognitive functions. Therefore,
it is important to find the right period of development in
order to rescue the cognitive deficits observed in Syngap1−/+
mutation. One of the means of finding therapeutic targets is to
find a protein which has been implicated in another ID and
ASD that produces similar or opposite cellular and behavioral
phenotypes as that of Syngap1−/+ mutants. The opposing effects
of these mutations may balance one another at synaptic and
behavioral function (Auerbach et al., 2011). Understanding the
effect of complementary pathways to rescue a gene of interest, for
example Syngap1−/+ mutation, would allow better therapeutic
designs to alleviate ID symptoms (earlier the better). It is
important to understand where an ID and ASD patient lies
on the spectrum of synaptic and behavioral dysfunction to
choose an appropriate therapy. Thus, continued study of various
disorders that exhibit ID and ASD phenotypes may lead to better
therapeutic targets.
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